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ABSTRACT 
 Leukocyte Adhesion Deficiency type 1 (LAD-1) is a rare primary immunodeficiency 
due to mutations in the gene encoding for the common chain of the 2 integrin family 
(CD18). Herein, we describe clinical manifestations and long-term complications of eight 
LAD-1 patients. Four LAD-1 patients were treated with hematopoietic stem cell 
transplantation (HSCT), while the remaining four, including two with moderate LAD-1 
deficiency, received continuous antibiotic prophylaxis. Untreated patients presented 
numerous infections and autoimmune manifestations.  In particular, two of them developed 
renal and intestinal autoimmune diseases, despite the expression of Beta-2 integrin was 
partially conserved. Other two LAD-1 patients developed type 1 diabetes and autoimmune 
cytopenia after HSCT, suggesting that HSCT is effective for preventing infections in LAD-1, 
but does not prevent the risk of the autoimmune complications. 
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Introduction 
Leukocyte Adhesion Deficiency 1 (LAD-1, OMIM #116920) is a rare autosomal-
recessive primary immunodeficiency, reported in fewer than 400 individuals, caused by a 
genetic defect in gene ITGB2 (located at 21q22.3; OMIM *600065), encoding for the 
common chain of the 2 integrin family (CD18).1 CD18 can form three heterodimers by 
interaction with the α subunits CD11a, CD11b (Mac-1), or CD11c; but the absence or 
abnormal synthesis of CD18 prevents leukocyte surface expression of CD11 subunits . Most 
of the ITGB2 mutations lead to absent or decreased expression of CD18 on the cell surface as 
measured by flow cytometry, or more rarely, to nonfunctional expression of CD18 
heterodimers, resulting in impaired leukocyte adhesion and migration
2
.  
LAD-1 patients display recurrent severe infections and impaired wound healing 
without pus formation. Hallmarks of the disease are moderate leukocytosis (in particular 
neutrophilia) in the absence of overt infection or leukocyte counts above 100,000/mL during 
acute infection and omphalitis, that is often associated with delayed separation of umbilical 
cord (usually after 3 weeks or later)
 3
. Skin and soft tissue infections are also common. While 
patients with partial CD18 deficiency can develop in the second decade of life, gingivitis and 
periodontitis, sometimes associated with severe bone loss, and premature loss of primary and 
permanent teeth
4
.  
Two forms of LAD-1 have been described: the severe form, characterized by virtual 
absence of CD18  (CD18 expression below 2% expression of cells), and lethal outcome 
without hematopoietic stem cells transplantation (HSCT)
5
, and the moderate form 
characterized by detectable CD18 expression at levels ranging from 2% up to 30% of cells, 
and longer survival without HCST
 6
. Genetic analysis of LAD-1 patients revealed more than 
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86 mutations in ITGB2 gene including missense, deletion, splice site, insertion and non-sense 
mutations 
7
.  
Herein we report clinical manifestations, immune features and long-term outcome of 
LAD-1 patients depending on ITGB2 mutations, type of treatment that they received and the 
age of diagnosis.  
 
Material and methods 
Patients and study design 
We describe eight patients (identified as P1, P2, P3, P4, P5, P6, P7, P8) with diagnosis of 
LAD-1 identified from 1993 to 2015, and followed at four Italian Clinical centers: Pediatrics 
Clinic, “ASST Spedali Civili” Hospital, University of Brescia; Department of Pediatrics, 
“Policlinico S. Orsola-Malpighi” Hospital, University of Bologna; Pediatric Hematology and 
Oncology Unit, “Policlinico Giovanni XXIII” Hospital, University of Bari “Aldo Moro”, 
Bari; Department of Pediatrics, Institute for Maternal and Child Health “IRCSS Burlo 
Garofolo”, Trieste. Medical history and clinical data were retrospectively obtained from 
medical records of the four clinical centers. On the basis of the age at which patients were 
identified, we analyzed long term outcome in those with diagnosis before three years of life 
(P1, P2, P3, P4, P5) or after three years of life (P6, P7, P8) (Table 1). All patients (or their 
caregivers in case of pediatric patients) signed an informed consent form according to the 
local ethical committee recommendations.  
We obtained laboratory findings at diagnosis and at the last follow-up visit (see Table 2 for 
leukocyte counts at the last follow-up visit in transplanted patients). 
Molecular diagnosis 
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LAD-1 diagnosis was based on flow cytometry analysis of CD18 expression on neutrophils. 
Genetic analysis of ITGB2 was performed in patients with reduced CD18 expression. FITC-
labeled or PE-labelled mAbs against CD18, CD11a, CD11b, CD11c were used in order to 
measure levels of β2 integrins expression on cell surface, as previously described
8
. For 
genetic analysis, DNA was extracted from peripheral blood leukocytes using standard 
techniques. Direct Sanger sequencing with primers spanning complete coding sequence and 
exon flanking regions was performed using the BigDye Terminator Kit (Applied 
Biosystems)and an ABI-Prism 310 sequencer (Applied Biosystems). Next, sequences were 
analyzed using the SeqScape software (Life Technologies). Mutations were designated as 
recommended by the Human Genome Variation Society (HGVS – http://www.hgvs.org) 
9
. 
Statistical analysis 
For statistical analyses, data are presented as numbers and percentages for categorical 
variables. Continuous variables are expressed as mean ± standard deviation (SD) if normally 
distributed (evaluated with D’Agostino-Pearson normality test) or, alternatively,  as median 
±interquartile range . Rank correlation test was used to analyze the correlation between 
leukocyte counts and the age at diagnosis. For all analyses a p-value <0.05 was considered 
statistically significant. Data were analyzed by MedCalc Software package for Windows, 
release 12.7 (MedCalc Software, Belgium).  
 
Results 
Patients 
We describe eight patients with LAD-1 evaluated for11.19 ± 8.21 years . All the patients are 
alive, including four patients that have been treated with HSCT. Two patients are female, 
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and six are male (see Table 1).  Seven of the eight patients (87.5%: P2-P7) are Caucasian, 
one of African origin (P1). Median age at diagnosis was 0.856 years (IQ range 0.25 to 4.83). 
In five patients, diagnosis was established before three years of age (P1, P2, P3, P4, P5), 
while the remaining three patients were identified later in life (P6, P7, P8). Mean age at last 
follow-up visit was 13.86 ± 9.74 years. Leukocytosis was consistently observed in all 
subjects at diagnosis (41,168 ± 21,377 cells/mm
3
 as average; ranging from 12,640 to 68,000 
cells/mm
3
). Analysis of leukocyte counts in LAD-1 patients showed higher leukocyte counts 
in patients with early-diagnosis as compared to those with delayed-diagnosis (respectively 
55,006 ± 12,220 cells/mm
3
 vs 10,107 ± 4,931 cells/mm
3
; p=0.036).  In addition, neutrophil 
counts were higher in patients with early diagnosis (38,406 ± 13,870 cells/mm
3
 vs 13,460 vs 
7,669 cells/mm
3
, p=0.036)  An inverse correlation  was observed (r
2
= 0.85; p=0.001) 
between leukocyte counts and age at diagnosis (Figure 1), suggesting that leukocyte counts 
can be moderately elevated in older children with LAD-1 deficiency. 
CD18 expression and ITGB2 genetic analysis 
Two out of eight patients showed partial expression of CD18 on cell surface (P5, P6) ranging 
from 5% to 60%; while CD18 was undetectable on leukocytes of the four patients (P1, P2, 
P3, P4,  P8) or not evaluated in one  subject (P7).   
ITGB2 genetic analysis revealed eight distinct mutations (referral sequence 
ENST00000302347.9, see Figure 2). Mutations detected in patients P1, P3, P6 and P8 were 
novel, while the remaining four identified in patients P2, P4, P5, P7, P8 have been 
previously reported. In P1 and P3 we identified a deletion of 10 nucleotides (190-200del) 
resulting in frameshift (Gly40fsX49).  Accordingly, CD18 expression by flow cytometry 
revealed no protein expression on cell surface. In P2, we detected an homozygous nonsense 
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mutation in exon 3 (NM_000211.3: c.79A > T; NP_000202.2: p.Lys27X) that was 
previously reported by Fiorini M. et al., and that was associated with  undetectable protein 
expression
10
. This mutation was associated with cytogenetic abnormalities of chromosome 
21 (ring 21). In P4, we identified a homozygous mutation (c.[268delG];[268delG]) with  
undetectable CD18 expression 
7
. In P5, we detected a homozygous missense mutation 
(c.1906T>C) that results in cysteine substitution with arginine (p.Cys612Arg)
11
. CD18 
expression was reduced on cell surface, but still detectable (as low as 5% of cells). In P6 a 
new intronic homozygous  mutation was found in the splicing site consensus sequence (IVS 
15-2 A>G) leading to 5 amino-acid residues deletion (D750-K755del), and partial CD18 
expression (60% of cells were CD18
+
). In P7, we detected a non-sense homozygous 
mutation (A151T) with premature termination at codon L27
12
. In P8 we identified compound 
heterozygous mutations c.809C>T (p.A270V)/ c.819G>A (p.K294X), resulting in 
undetectable CD18 protein expression by flow cytometry. 
Infections in LAD-1 patients 
Five of the eight patients  in our study presented delayed separation of umbilical cord (P1, 
P2, P4, P6, P7) during the perinatal period. Signs of omphalitis were observed only in P4, 
but not in the other patients. 
Six of the eight patients (P1, P2, P5, P6, P7, P8) showed impaired wound healing and 
skin/soft tissue infections, presenting as perianal or pilonidal abscesses, fasciitis, 
pyodermitis, dactylitis. All patients had also other infectious manifestations such as upper 
respiratory tract infections (URTI), pneumonia, enteritis, urinary tract infections, otitis, 
osteomyelitis, that often required hospitalization for intravenous antibiotic therapy. Seven 
out of eight patients showed at least one episode of sepsis during their lifetime. Both Gram 
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positive bacteria (Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus 
epidermidis, Clostridium difficile Enterococcus faecalis) and Gram negative bacteria 
(Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, Proteus mirabilis, 
Enterobacter cloacae) were isolated from cultures. Fungal infections were detected 
(Aspergillus fumigatus and Candida parapsilosis) in patients P7 and P2.  Five of the eight 
patients (P1, P2, P5, P6, P7) had signs of periodontal diseases such as gingivitis and 
periodontitis, and complete tooth loss in one case (P7).  
 Despite the small sample size that limited statistical comparison among severe cases, 
we observed that patients that were not treated by Hematopoietic Stem Cell Transplantation 
(HSCT) because of the delayed diagnosis presented a higher number of infections as 
compared  to patients who underwent HSCT, suggesting that HSCT constitutes the only cure 
for patients with LAD-1 
5
. As reported elsewhere
14
, one of the patients (P6) was treated for 
one year with an ustekinumab, an antibody that target the p40 subunit that is shared by both 
interleukin-23 and interleukin-12 and inhibits interleukin-23-dependent production of 
interleukin-17.  
 
Treatment and outcome 
Treatment 
Allogeneic HSCT was performed in four patients with early-diagnosis of LAD-1 and  
complete CD18 deficiency (P1, P2, P3, P4): P1 was transplanted with  matched related 
sibling, P2 and P3 matched unrelated donors, or haploidentical donor (P4). Engraftment 
was successful in three patients (P1, P3, P4) while failed in patient P2, who was later 
transplanted in another European center. In particular, P1, P2, P3 were included in the 
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multicenter report of HSCT outcome in LAD1 patients 
5
.  In these patients, 
cyclosporine A was used as immunosuppressive agent after transplant. Analysis of 
donors chimerism revealed that engraftment was full in patients P3 and P4, while was 
partial in P1 and P2
6
.  In the other  patients, no suitable donor has been found at the 
time of diagnosis or the family has refused this treatment. While in patient P8, HSCT 
has been proposed to the family and the search for a compatible donor is  still  ongoing. 
In these patients, several infections or other disease manifestations have been observed 
despite antibiotic prophylaxis (Figure 3). 
Auto
i
mmunity 
All patients have been screened for autoantibodies, but  they were detected in six out of 
the eight patients during their follow-up: they were detected in consecutive samples
 
of 
three untransplanted patients (P5, P6, P7), but also in other three transplanted patients 
(P1, P2, P3).  In P5, a patient with moderate LAD-1 not treated with HSCT, Crohn-like 
colitis and juvenile idiopathic arthritis were diagnosed at 12 of age, and successfully 
treated with the anti-TNF-α antibody infliximab
15
. At 16 years of age we observed the 
appearance of anti-nuclear antibodies (ANA), perinuclear anti-neutrophil cytoplasmic 
antibodies (pANCA), anti-beta 2 glycoprotein antibodies (B2GPI)  and anti-cardiolipin 
antibodies.  Elevated titers of anti-thyroglobulin antibodies (anti-TG) were identified in 
P6 (moderate type LAD-1 not transplanted patient) and P7 (severe type LAD-1 not 
transplanted patient), but anti-thyroid peroxidase (anti-TPO) antibodies were negative 
and thyroid hormones  were normal. While low titers of anti-ANA (1:160 dilution) were 
detected in P3.  
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Autoimmune diseases were also observed in LAD-1 patients subjected to HSCT (P1, 
P2, P3), but these manifestations could constitute possible complications of the 
transplantation procedure.  In particular, patient P1 developed type-1 diabetes mellitus 
(DM) 5 years after HSCT; onset of the disease was also associated with appearance of 
anti-islet cell antibodies (ICA), anti-insulin antibodies (IAA) and anti-glutamic acid 
decarboxylase (GAD-65) antibodies. While, patient P2 presented hemolytic anemia 
about 3 years after HSCT and thereafter autoimmune thrombocytopenia.  
Renal involvement 
Patient P5 presented proteinuria, suggestive of acute  glomerulonephritis when she was 
14 years old, but renal biopsy was refused . While P7 developed post-infectious 
glomerulonephritis with gross hematuria at the age of 14.  At 30 years of age, an 
abdomen ultrasound performed despite normal serum creatinine, showed abnormal  
renal echotexture with loss of corticomedullary differentiation , as sign of early chronic 
kidney disease. An abdominal computed tomography (CT) scan was therefore 
performed, showing microcysts, but renal biopsy was not performed because patient 
refused further investigations.  
 
Discussion 
 Although transplanted and untrasplanted patients cannot be compared in terms of 
autoimmune manifestations, an elevated risk of autoimmunity was observed in LAD-1 
patients despite some of them were treated with HSCT 
16
. Several other reports have shown 
that patients who received HSCT for hematological diseases can develop autoimmune 
diseases such as thyroiditis 
17
, type-1 DM 
18, 19, 20
, myasthenia gravis 
21
 and celiac disease 
22
. 
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How organ-specific autoimmune disease can develop in these patients is still unclear; it 
might be related to the conditioning regimen or, alternatively to impairment of  the 
mechanisms controlling the tolerance. Interestingly, the intervals between transplant and 
onset of autoimmune diseases ranged from five months up to eight years, suggesting that risk 
of autoimmune complications can persist for many years in patients receiving HSCT. 
Patients with primary immunodeficiencies are often predisposed to autoimmunity because of 
impairment of mechanisms that regulate tolerance, such as defect of regulatory T cells 
21,22,23,24
. In particular, we reported detection of autoantibodies in three out of four LAD-1 
patients who underwent HSCT; which has been associated with autoimmune diseases in two 
of them. Indeed, in few cases, type-1 DM development has been observed in patients 
receiving HSCT
16, 18, 19, 20
.  
Interestingly, non-obese diabetic (NOD) mice that lack of integrin β2 (CD18, Itgb2) or 
integrin αL (CD11a, ItgaL) are protected against the risk to develop diabetes or insulitis 
because ItgaL null leukocytes cannot infiltrate the pancreatic islets of these mice
25
. This 
suggests that LAD-1 patients that are predisposed to DM can remain protected until CD18 
deficiency is treated by HSCT. Once the expression of adhesion molecules is restored, 
donor’s leukocytes could mediate the initiation and progression of pancreas-specific 
inflammation. This model could also apply to other autoimmune disorders, although 
different conditioning regimens could play an important role in the risk of developing 
autoimmunity after HSCT.  
Despite there was previous evidence that LAD-1 patients are at risk of renal disease, 
several experimental models of renal injury suggest that many kidney disorders are related to 
dysregulation of leukocyte adhesion, and increased expression of beta2 integrins
26,27
.  In 
particular, analysis of CD80 and CD18 expression by leukocytes derived from  mice with 
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nephrotic syndrome induced by doxorubicin showed an increase of  CD18 expression in 
cytotoxic T lymphocytes, NK cells, and monocytes and higher CD80 expression in 
monocytes
26
. Moreover, kidney oxidative damage was positively correlated with CD80 
expression in monocytes and with increase of creatinine serum levels, suggesting that drugs 
that interfere with integrin and costimulatory molecules might provide new therapeutic 
opportunities for treatment of renal injury.  In another study by Tang et al., analysis of PMN-
dependent proteinuria observed after intravenous injection of anti-glomerular basement 
membrane antibody in wild-type and Mac-1-deficient mice showed that nephritis  was 
observed in wild-type animals but absent in Mac-1 mutant mice 
27
.  Therefore, LAD-1 
patients with complete CD18 deficiency are probably protected against renal injury 
according to these models. However, two of our untransplanted patients (one of the early-
diagnosed patients, P5, and one of the other group, P7) presented renal injury, suggesting 
that  partial β2 integrins expression could lead to kidney damage in some patients.  
 In this study we show that early diagnosis of LAD-1 patients can result in better long 
term outcome in term of survival and prevention of infections for patients who are treated 
with HSCT. In contrast, severe or moderate LAD-1 patients who are not treated with HSCT 
experience higher numbers of infectious and autoimmune events in the course of their 
follow-up, suggesting that HSCT should always be proposed to patients with LAD-1 
deficiency. Finally, an higher risk of autoimmune diseases was also observed in two patients 
receiving  HSCT suggesting that careful long term monitoring of these patients is required 
even in HSCT-treated patients. 
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Table 1. Clinical and genetic features of LAD-1 patients. 
Patient 
(partial or 
severe 
deficiency
) 
Se
x 
Age at 
diagnosi
s (years) 
Follow
-up 
time 
(years) 
Mutations in the CD18 
alleles of patients 
CD18 
expressio
n (%) 
Clinical 
presentation 
and types of 
infections 
during 
follow-up 
Identified 
bacteria and 
fungi 
Treatment  Autoantibodie
s 
 
P1* 
(severe) 
M 1.44 11.97 c.190-200del 
(GGCCCGGCTG); 190-
200del 
(GGCCCGGCTG) 
p.G40fs*49; G40fs*49 
<0.1% Delayed 
separation of 
umbilical 
cord, Sepsis, 
Periodontal 
disease, 
URTI, 
Pharyngitis, 
Cold skin 
abscess 
Enterococcus 
faecalis, 
Escherichia 
coli, 
Pseudomonas 
aeruginosa, 
Streptococcus 
pneumoniae 
HSCT Anti-ICA, 
GAD-65, 
IAA
§
 
 
P2*            
(severe) 
M 0.27 4.21 c.[A79T];del  
p.L27*;? 
<0.1% Delayed 
separation of 
umbilical 
cord, Sepsis, 
Periodontal 
disease, 
URTI, 
Pneumonia, 
Cold skin 
abscess 
Enterobacter 
cloachae,  
Klebsiella 
pneumonia, 
Candida 
parapsilosis 
HSCT Anti-Rh§  
P3* 
(severe) 
M 0.23 20.50 c.190-200del 
(GGCCCGGCTG); 190-
200del 
(GGCCCGGCTG) 
p.G40fs*49; G40fs*49 
<0.1% Sepsis, 
URTI, 
Pneumonia, 
Otitis media, 
Enteritis, 
UTI 
Enterobacter 
cloachae, 
Pseudomonas 
aeruginosa 
HSCT ANA 
(1:160)
 §
 
 
P4* 
(severe) 
F 0.19 1.90 c.[268delG];[268delG] 
p.[D90fs*14];[D90fs*14
] 
<2% Omphalitis, 
Sepsis, UTI 
Staphylococcu
s epidermidis,  
Escherichia 
coli 
HSCT -§  
P5* 
(partial) 
F 0.25 15.24 c.[T1834C];[ T1834C] 
p.[C612R];[C612R] 
5% Sepsis, 
Periodontal 
disease, 
Mouth and 
tongue 
ulcers, 
URTI, 
Pneumonia, 
Enteritis, 
Perianal 
abscess and 
fistulas,  
Osteomyeliti
s 
Staphylococcu
s aureus, 
Proteus 
mirabilis 
Antibiotic 
 
prophylaxis 
ANA, 
pANCA, 
B2GPI, anti-
cardiolipin  
 
P6 
# 
(partial) 
M 4.81 13.50 c.[2081-2A>G];[2081-
2A>G] 
p.[D750-
K755del];[D750-
60% Delayed 
separation of 
umbilical 
cord, Sepsis, 
Enterococcus 
faecalis, 
Escherichia 
coli, 
Antibiotic  
prophylaxis 
Anti-TG  
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K755del] Aphthous 
stomatitis, 
Periodontal 
disease, 
Otitis media, 
Mastoiditis, 
Appendicitis 
Skin abscess, 
Perianal 
abscess, 
Pilonidal 
abscess 
Pseudomonas 
aeruginosa 
P7
# 
(severe) 
M 4.01 21.76 c.[A79T];[A79T] 
p.[L27*];[L27*]  
N/A  Delayed 
separation of 
umbilical 
cord, Sepsis, 
Aphthous 
stomatitis, 
Periodontal 
disease with 
severe bone 
loss, Otitis 
media, 
Enterocolitis, 
Appendicitis 
with 
peritonitis, 
Pilonidal 
abscess, 
Fasciitis, 
Pyodermitis, 
Dactylitis 
Clostridium 
difficile, 
Aspergillus 
fumigatus 
Antibiotic  
prophylaxis 
Anti-TG  
P8
# 
(severe) 
M 4.90 0.44 c.[809C>T] ;[G819A] 
p.[A270V];[K294*] 
<0.1% Pneumonia, 
Perianal 
ulcer 
Cultures not 
available 
Antibiotic  
prophylaxis
, 
 waiting for  
HSCT 
-  
  * Clinical diagnosis before 3 years of age; 
#
 Clinical diagnosis after 3 years of age; 
§
 Analysis of autoantibodies was performed 
after HSCT. 
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Table 2. Leukocyte counts at the last follow-up visit in transplanted LAD-1 patients. 
Patient Age at HSCT 
(years) 
WBC
 
at last follow-up 
visit 
(cells/mm
3
) 
Neutrophils at last follow-
up visit (cells/mm
3
 and %) 
Lymphocytes at last follow-
up visit (cells/mm
3
 and %) 
Monocytes at last follow-up visit 
(cells/mm
3
 and %) 
P1 1.54 6,780 4,850  (71. 6 %) 1,350    (19.9 %) 325     (4.8 %) 
P2 0.56 12,860 9,684  (75.3 %) 1,582    (12.3 %) 1505   (11.7 %) 
P3 10.73 7,390 4,350  (58.9 %) 2,060    (27.8 %) 510     (6.9 %) 
P4 0.25 17,260 5,178  (30 %) 10,700  (62 %) 690     (4 %) 
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Figure 1. An inverse correlation between leukocyte count and age at LAD-1 diagnosis. The graph reports 
leukocyte counts (cells/uL)  on y axis of 8 LAD-1  patients at the age of diagnosis (x axis).  
Figure 2. Domain structure of the 2 integrin (CD18) and location of ITGB2 mutations.  Location of ITGB2 
patients in 8 LAD-1 patients. 
Figure 3. Clinical events  in LAD-1 patients. The panels report the clinical events of  4 LAD-1 patients (P5, 
P6, P7, P8) that were not treated with HSCT. 
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Figure 1.  
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Figure 2. 
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Figure 3 
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